Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

Zelluna ASA First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development ZIMA-101 represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform Patient identification, pre-screening and screening activities continue across all four tumour indications included in the study Company on track for initial clinical data to emerge from mid-2026 July 13 2026 – Zelluna ASA (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study where Professor Fiona Thistlethwaite serves as Chief Investigator for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, making it an attractive target for precision cell therapy. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites i